A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Inclusion Criteria:

- Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis
of acne vulgaris.

- Must have a minimum of ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and
≤ 2 nodulocystic lesions at baseline on the face.

- Must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as
per the Investigator's Global Assessment.

Exclusion Criteria:

- Female subjects who are pregnant, nursing or planning to become pregnant during study
participation.

- Have a history of hypersensitivity or allergy to tazarotene, retinoids and/or any of
the study medication ingredients.

- Presence of any skin condition that would interfere with the diagnosis or assessment
of acne vulgaris.